5-(3,3-dimethyl-1-triazeno)-imidazole-4-carboxamide (DTIC, DIC, NSC-45388)-A new antitumor agent with activity against malignant melanoma

European Journal of Cancer (1965)

Volumn 8, Issue 1, 1972, Pages 85-92

  Carter, Stephen K ^a   Friedman, Michael A ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALKYLATING AGENT; AMIDE; ANTINEOPLASTIC AGENT; DNA; IMIDAZOLE DERIVATIVE; TRIAZENE DERIVATIVE;

ANIMAL; EXPERIMENTAL LEUKEMIA; HUMAN; IATROGENIC DISEASE; LEUKOCYTE COUNT; LEUKOPENIA; LIVER TUMOR; LUNG TUMOR; LYMPH NODE METASTASIS; MELANOMA; METABOLISM; MOUSE; RAT; REVIEW; SKIN TUMOR; THROMBOCYTOPENIA; VOMITING;

ALKYLATING AGENTS; AMIDES; ANIMAL; ANTINEOPLASTIC AGENTS; DNA; HUMAN; IMIDAZOLES; LEUKEMIA, EXPERIMENTAL; LEUKOCYTE COUNT; LEUKOPENIA; LIVER NEOPLASMS; LUNG NEOPLASMS; LYMPHATIC METASTASIS; MELANOMA; MICE; RATS; SKIN NEOPLASMS; THROMBOCYTOPENIA; TRIAZENES; VOMITING;

EID: 0015292927     PISSN: 00142964     EISSN: None     Source Type: Journal    
DOI: 10.1016/0014-2964(72)90087-4     Document Type: Article

References (30)

1. Synthesis of potential anticancer agents. XXIX. 5-diazoimidazole-4-carboxamide and 5-diazo-v-triazole-4-carboxamide
2. Antitumor activity of 4(or 5)-aminoimidazole-5(or 4)-carboxamide derivative
3. Imidazoles. II. 5(or 4)-(monosubstituted triazeno)imidazole-4(or 5)-carboxamides
4. Imidazoles. I. Coupling reactions of 5-diazoimidazole-4-carboxamide
5. Antitumor activity of triazenoimidazoles
6. Antitumor activity of 4(or 5)-aminoimidazole-5(or 4)-carboxamide derivatives
7. Influence of treatment schedules and route of administration on the chemotherapy of murine leukemia L1210 with 5(or 4)-[3,3-bis(2-chlorethyl)-1-triazeno]-imidazole-4(or 5)-carboxamide (NSC-82196)
8. Kinetics of the effect of 5(or 4)-(3,3-dimethyl-1-triazeno)-imidazole-4(or 5)-carboxamide (NSC-45388) and 5(or 4)-[3,3-bis(2-chloroethyl)-1-triazeno] imidazole-4(or 5)-carboxamide (NSC-82196) on the reproductive integrity of cultured leukemia L1210 cells
9. Effectiveness of antileukemic agents in mice inoculated with a leukemia L1210 variant resistant to 5-[3,3-bis(2-chloroethyl)-1-triazeno] imidazole-4-carboxamide (NSC-82196)
10. Effectiveness of antileukemic agents in mice inoculated with leukemia L1210 variant resistant to 5(or 4)-dimethyltriazeno) imidazole-4(or 5)-carboxamide (NSC-45388)
11. Enhanced response of leukemic (L1210) mice to combination chemotherapy with 5(or 4)-(dimethyltriazeno) imidazole-4-(or 5)-carboxamide (NSC-45388) (DIC) and 5-fluorouracil (NSC-19893) (FU)
12. Colorimetric determination of dialkyltriazenoimidazoles
13. Preliminary clinical trial and the physiologic disposition of 4(5)-(3,3-dimethyl-1-triazeno) imidazole-5(4)-carboxamide in man
14. Studies of the mechanism of action of the antitumor agent 5(4)-(3,3-dimethyl-1-triazeno) imidazole-4(5)-carboxamide in Bacillus subtilis
15. 5(or4)-[3,3-bis(2-chlorethyl)-1-triazeno]-imidazole-4(or 5)-carboxamide (NSC-82196): Microbiologic Evaluation and Assay
16. Some pharmacokinetic aspects of 5-(dimethyltriazeno)-imidazole-4-carboxamide in the dog
17. Metabolism of 4(5)-(3,3-dimethyl-1-triazeno)-imidazole-5-(4)-carboxamide (DIC) (NSC-45388) in man
18. Elevated urinary excretion of 4-amino-imidazole-5-carboxamide in patients after intravenous injection of 4-(3,3-dimethyl-1-triazeno) imidazole-5-carboxamide
19. Some pharmacologic observations on the antitumor agent 5-(3,3-dimethyl-1-triazeno-imidazole-4-carboxamide)
20. N-demethylation of the antineoplastic agent 4(5)-(3,3-dimethyl-1-triazeno) imidazole-5(4)-carboxamide by rats and man
21. Carcinogenicity and possible mode of action of 4(5)-(3,3-dimethyl-1-triazeno) imidazole-5(4)-carboxamide (NSC-45388, DIC)
22. Clinical trials with the antitumor agent 5-(3,3-dimethyl-1-triazeno) imidazole-4-carboxamide (NSC-45388)
23. Results of Phase I and II studies with imidazole-carboxamide-dimethyl-triazeno
24. Imidazole carboxamide therapy in advanced malignant melanoma
25. Study of 5′-(3,3-dimethyl-1-triazeno) imidazole-4-carboxamide (NSC-45388) in patients with gastrointestinal cancer
26. Complete inhibition of mouse leukemia L1210 by 5(or 4)-[3,3-bis(2-chloroethyl)-1-triazeno]imidazole-4(or 5)-carboxamide (NSC-82196)
27. Duration of anti-leukemia L1210 efficacy of a water-soluble formulation of 5-[3,3-bis(2-chloroethyl)-1-triazeno]-imidazole-4-carboxamide (NSC-82196) after i.p. or oral administration in mice